BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15546135)

  • 1. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.
    Pritchard J; Cotterill SJ; Germond SM; Imeson J; de Kraker J; Jones DR
    Pediatr Blood Cancer; 2005 Apr; 44(4):348-57. PubMed ID: 15546135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
    Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
    Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
    Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
    Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
    Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group.
    Imaizumi M; Watanabe A; Kikuta A; Takano T; Ito E; Shimizu T; Tsuchiya S; Iinuma K; Konno T; Ohi R; Hayashi Y;
    Tohoku J Exp Med; 2001 Oct; 195(2):73-83. PubMed ID: 11846211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
    Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
    Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.
    Hartmann O; Kalifa C; Benhamou E; Patte C; Flamant F; Jullien C; Beaujean F; Lemerle J
    Cancer Chemother Pharmacol; 1986; 16(2):165-9. PubMed ID: 3512113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study.
    Philip T; Ladenstein R; Zucker JM; Pinkerton R; Bouffet E; Louis D; Siegert W; Bernard JL; Frappaz D; Coze C
    Br J Cancer; 1993 Jan; 67(1):119-27. PubMed ID: 8427772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation.
    Hartmann O; Valteau-Couanet D; Benhamou E; Vassal G; Rubie H; Beaujean F; Lemerle J
    Eur J Cancer; 1997 Oct; 33(12):2126-9. PubMed ID: 9516867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
    Pritchard J; McElwain TJ; Graham-Pole J
    Br J Cancer; 1982 Jan; 45(1):86-94. PubMed ID: 7037033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma.
    Carli M; Colombatti R; Oberlin O; Stevens M; Masiero L; Frascella E; Koscielniak E; Treuner J; Pinkerton CR
    J Clin Oncol; 1999 Sep; 17(9):2796-803. PubMed ID: 10561355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
    Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation.
    Cesaro S; Meloni G; Messina C; Pillon M; Proglia A; Lanino E; Caniggia M; Bagnulo S; Pession A; Locatelli F;
    Bone Marrow Transplant; 2001 Jul; 28(2):131-6. PubMed ID: 11509930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group.
    Garaventa A; Rondelli R; Lanino E; Dallorso S; Dini G; Bonetti F; Arrighini A; Santoro N; Rossetti F; Miniero R; Andolina M; Amici A; Indolfi P; Lo Curto M; Favre C; Paolucci P; Pession A; De Bernardi B
    Bone Marrow Transplant; 1996 Jul; 18(1):125-30. PubMed ID: 8832005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
    Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
    Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
    Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
    JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies.
    Stram DO; Matthay KK; O'Leary M; Reynolds CP; Haase GM; Atkinson JB; Brodeur GM; Seeger RC
    J Clin Oncol; 1996 Sep; 14(9):2417-26. PubMed ID: 8823319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.